Financing AvailabilityAccess to a $50 million equity line could ease capital constraints and reduce the need for more dilutive financing, supporting continued development activities.

Strategic CollaborationA collaboration with an established partner that covers clinical costs while sharing profits evenly improves cash efficiency and enhances commercialization potential for key assets.

Bears Say

Analyst SentimentAn analyst downgrade citing strategic uncertainty and a financing overhang may weaken market confidence and put downward pressure on the stock.

Liquidity RiskLow cash reserves combined with a sustained multi-million dollar cash burn elevate the likelihood of near-term capital raises that could dilute existing shareholders.

Pipeline StrategyUnclear strategic direction for the bispecific antibody portfolio increases execution risk and makes it harder for investors to evaluate future growth prospects.

ABPO FAQ

What was Abpro Holdings’s price range in the past 12 months?

Abpro Holdings lowest stock price was $0.09 and its highest was $15.19 in the past 12 months.

What is Abpro Holdings’s market cap?

Abpro Holdings’s market cap is $414.23K.

When is Abpro Holdings’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Abpro Holdings’s earnings last quarter?

Currently, no data Available

Is Abpro Holdings overvalued?

According to Wall Street analysts Abpro Holdings’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Abpro Holdings pay dividends?

Abpro Holdings does not currently pay dividends.

What is Abpro Holdings’s EPS estimate?

Abpro Holdings’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Abpro Holdings have?

Abpro Holdings has 2,716,278 shares outstanding.

What happened to Abpro Holdings’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Abpro Holdings?

Currently, no hedge funds are holding shares in ABPO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Abpro Holdings

Abpro Holdings, Inc., a biotechnology company, focuses on novel antibody constructs for immuno-oncology and ophthalmology. Its platforms include DiversImmune, a discovery platform that generates a diverse collection of proprietary antibodies against clinically validated and novel targets; and MultiMab, an engineering platform that provides the flexibility to combine antibody building blocks in different combinations and orientations to create fit for purpose novel full-length multi-specific antibody constructs. The company's lead product candidates include ABP-102, a next generation immuno-oncology TetraBi antibody targeting HER2 and CD3 is developed for the treatment of HER2+ solid tumors, including breast and gastric cancers; and ABP-201, a TetraBi antibody format that simultaneously inhibit VEGF and ANG-2 for the treatment of vascular diseases of the eye, including diabetic macular edema and wet age-related macular degeneration. It also develops ABP-110, a TetraBi antibody targeting GPC3 and CD3 for the treatment of hepatocellular carcinoma; and ABP-150, a TetraBi antibody targeting claudin 18.2 and CD3 for the treatment of gastric cancers. The company has strategic partnership with Celltrion Inc. and Abpro Bio International, Inc. Abpro Holdings, Inc. was incorporated in 2004 and is headquartered in Woburn, Massachusetts.